Ultima Vez Modificado: 15 de octubre del 2004
Conference Date: December 11, 2004
Conference Location: San Francisco, CA
Conference Date: January 8, 2005
Conference Location: Atlanta, GA
Conference Date: February 5, 2005
Conference Location: Philadelphia, PA
Conference Web Page URL: www.thecbce.com/futureprograms.asp
Topics Covered: This continuing medical education (CME) activity will compare the biology, clinical efficacy, and toxicity of small-molecule EGFR inhibitors in the treatment of NSCLC.
Who Should Attend: This activity is designed primarily for medical oncologists and other physicians interested in the treatment of cancer.
Continuing Education: YesEnglish
Jun 24, 2010 - Gefitinib, a tyrosine kinase inhibitor of the epidermal growth factor receptor, is more effective than standard chemotherapy in extending life for patients with non-small-cell lung cancer who have epidermal growth factor receptor mutations, according to a study published in the June 24 issue of the New England Journal of Medicine.
Jun 24, 2010